Target Validation and DNA Damage Response Group
Professor Tutt’s group aims to discover novel therapies and biomarkers in BRCA1/BRCA2-associated cancers and ER/HER2-negative/basal-like breast cancers – and to identify new drug targets and therapy combination strategies.
Research, projects and publications in this group
Breast cancer is the most common cancer in the UK. Approximately 50,000 women will be diagnosed with breast cancer each year. Our research aims to identify the biological mechanisms that cause and drive triple negative forms of breast cancer (which make up around 15-20% of all diagnosed breast cancers).
Professor Tutt's group is interested in therapy development for BRCA1/2 associated and Triple Negative forms of breast cancer, based on DNA Damage Repair (DDR) and in particular Homologous Recombination (HR) deficiency.
In this context, the group has, in collaboration with Professor Ashworth, developed a translational and clinical trial programme focusing on TNBC and cancers associated with functional deficiencies in BRCA1 and BRCA2.
The group has identified novel drivers of homologous recombination deficiency in breast cancer, normally used by cells in the body to create gametes in the process of meiosis that requires induction of genomic diversity (Watkins J. et al (2015). Cancer Discov. (5), 488-505).
Professor Tutt's group has also discovered new drivers of the biology of basal-like TNBC that affect how the immune system engages the cancer (Marra P. et al (2014) Cancer Res. 2014 Sep 1;74(17):4908-21).
Professor Andrew Tutt
Director of Breast Cancer Now Toby Robins Research Centre & Head of Division:
Drug Target Discovery, Breast Cancer Collaborations, Target Validation & DNA Damage Response
Andrew Tutt is Head of the Division of Breast Cancer Research and Director of the Breast Cancer Now Toby Robins Research Centre at the ICR and Guy’s Hospital King’s College London. He is a Clinician Scientist with the Laboratory and Clinical Trials programme, and a Consultant Clinical Oncologist looking after women with breast cancer.
Researchers in this group
.
Phone: +44 20 3437 7380
Email: [email protected]
Dr Rebecca Marlow leads the Patient Derived Models Team in the Breast Cancer Research Division. This team derives in vivo xenograft and 3D in vitro organoid models of breast cancer and supports research projects across the Division.
Professor Andrew Tutt's group have written 171 publications
Most recent new publication 8/2024
See all their publicationsIndustrial partnership opportunities with this group
Opportunity: Cancer biomarker for predicting response to drugs targeting mitotic checkpoint kinases and cell division
Commissioner: Professor Andrew Tutt, Professor Chris Lord, Professor Jonathon Pines